Drug Profile
BMD 1111
Alternative Names: BMD-1111Latest Information Update: 23 Feb 2023
Price :
$50
*
At a glance
- Originator University of Arkansas System
- Developer BiologicsMD
- Class Osteoporosis therapies; Recombinant fusion proteins
- Mechanism of Action Osteogenesis stimulants; Parathyroid hormone receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Osteoporosis
Most Recent Events
- 23 Feb 2023 Discontinued - Preclinical for Osteoporosis in USA (unspecified route) (BiologicsMD pipeline, February 2023 )
- 28 Jul 2018 No recent reports of development identified for preclinical development in Osteoporosis in USA
- 12 Jun 2012 Preclinical trials in Osteoporosis in USA (unspecified route)